← Back to Search

Scotoma Awareness Training for Low Vision (SPOT Trial)

N/A
Recruiting
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Light sensitivity in the macular retina that is at least 10 dB units worse than in peripheral regions, as demonstrated by a scanning laser ophthalmoscope (SLO, MAIA)
Medical record review indicates this disease severity level has been present for at least 2 years.
Must not have
Inability to sit still in eye tracker for extended periods
Bilateral retinal scotomas larger than 20° diameter
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
Awards & highlights

Summary

This trial tests a new training method for older adults with Macular Degeneration, a condition causing central vision loss. The training uses a simulated blind spot to help patients become aware of their vision loss and develop new ways to see better. By making patients aware of their blind spot, the training aims to improve their vision and daily functioning. Eccentric viewing training has been shown to improve near visual acuity, reading speed, and daily functioning in people with central vision loss.

Who is the study for?
This trial is for adults with severe vision impairment (20/100 or worse) due to Macular Degeneration. Participants must have had this level of vision loss for at least two years and show specific light sensitivity differences between their macula and peripheral retina. Those who can't remain still during eye tracking or have very large retinal blind spots are excluded.
What is being tested?
'Scotoma awareness' Training, which aims to improve understanding and adaptation to blind spots in central vision, is being tested against a control training program. The study seeks to enhance low vision therapies based on how the brain adapts after central vision loss.
What are the potential side effects?
Since this trial involves non-invasive training programs rather than medication, traditional side effects are not expected. However, participants may experience fatigue or frustration during the exercises.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My central vision is significantly worse than my peripheral vision.
Select...
My condition has been severe for at least 2 years.
Select...
I have been diagnosed with Macular Degeneration.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I can't stay still for long periods during eye tracking tests.
Select...
I have large blind spots in both of my eyes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, after training completion, training is complete 6 weeks from baseline on average, and at follow up, 14 weeks from baseline on average for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline Fixation stability after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Saccadic re-referencing after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Visual Acuity after completion of Training at approximately 6 weeks and 14 weeks
Secondary study objectives
Change from Baseline Contrast Sensitivity after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline First saccade landing dispersion after completion of Training at approximately 6 weeks and 14 weeks
Change from Baseline Latency of target acquisition after completion of Training at approximately 6 weeks and 14 weeks
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Condition 2 - Control TrainingExperimental Treatment1 Intervention
In the control condition, participants will perform the same task as the scotoma awareness training, without the artificial visible scotoma.
Group II: Condition 1 - 'Scotoma awareness' TrainingExperimental Treatment1 Intervention
Participants will be asked to report the emotion of an emoji face ('happy' vs 'sad') that could appear anywhere on screen. For the entire duration of the training, an explicit, sharp outlined occluder surrounding the participant's true retinal scotoma will be rendered on screen. This occluder will be generated through a gaze-contingent display. The size and the contrast of the target will change adaptively in response to the patient's performance.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Control Training
2013
N/A
~240

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for central vision loss often focus on enhancing neural plasticity to improve visual function. These treatments may include visual training exercises, which aim to stimulate the brain's ability to adapt and reorganize itself to compensate for lost vision. Additionally, pharmacological interventions, such as the use of antioxidants or neuroprotective agents, can help protect remaining retinal cells and support neural health. Understanding and leveraging neural plasticity is crucial for central vision loss patients because it offers a pathway to potentially restore some visual function and improve quality of life, even when direct restoration of lost vision is not possible.

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,629 Previous Clinical Trials
2,302,262 Total Patients Enrolled
University of California, RiversideOTHER
30 Previous Clinical Trials
12,910 Total Patients Enrolled

Media Library

Scotoma Perimetry Oculomotor Training Clinical Trial Eligibility Overview. Trial Name: NCT05456581 — N/A
Central Vision Loss Research Study Groups: Condition 1 - 'Scotoma awareness' Training, Condition 2 - Control Training
Central Vision Loss Clinical Trial 2023: Scotoma Perimetry Oculomotor Training Highlights & Side Effects. Trial Name: NCT05456581 — N/A
Scotoma Perimetry Oculomotor Training 2023 Treatment Timeline for Medical Study. Trial Name: NCT05456581 — N/A
~1 spots leftby Jan 2025